Corbus Pharmaceuticals Holdings, Inc. (CRBP)
CRBPNASDAQ-CMBiotechnology: Pharmaceutical Preparations
$3.67
+0.5480 (+17.53%) today
Closed, Nov 13, 4:00 PM ET
- Market cap
- $69.86m
- P/E
- –
- EPS, last 4 quarters
- $-6.10
- Dividend yield
- –
- Day range
- –
- 52-week range
- $2.81 to $12.88
- Average volume
- –
- Previous close
- $3.13
Analysts
7 coveringBuy7 buy, 0 hold, 0 sell
Targets a year out average $31.80, +765.5% from here
Earnings
next estimate $-1.57Next report
Dec 2025
+29.8%
Mar 2026
+2.4%
Jun 2026
-39.2%
Sep 2026
-24.8%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$21.97m | -$24.30m | -$36.19m | -$38.82m |
| Net income | -$20.55m | -$22.97m | -$35.04m | -$37.75m |
News
8 latest- Thursday Sector Laggards: Agriculture & Farm Products, Biotechnology Stocks BNK Invest · 2 days ago
- Corbus Q3 Loss Widens On Higher R&D Costs; CRB-701 Data Due In Q1 2027 RTTNews · 3 days ago
- Corbus Pharmaceuticals Launches Phase 3 Cancer Trial, Teases More Obesity Drug DataMarketBeat · 5 days ago
- Is CRBP a Good Cannabis Investment After Positive Obesity Study Data?Zacks · Sep 17, 2026
- Corbus CRB-913 Delivers 5% Weight Loss in Phase 1b Obesity StudyMarketBeat · Sep 15, 2026
- Corbus Announces Positive Phase 1b Weight-Loss Data Showing For Oral Candidate CRB-913; Stock Up RTTNews · Sep 14, 2026
- Corbus Completes Final Patient Visit In Phase 1b CRB-913 Trial For Obesity RTTNews · Aug 5, 2026
- Corbus Says FDA Cleared Registrational TEMPO-1 Study Of CRB-701 For 2L-Oropharyngeal Cancer RTTNews · Jul 28, 2026
The company
Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company focusing on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well-understood biological pathways. Corbus' pipeline includes CRB-701, a next-generation antibody drug conjugate for the treatment of Nectin-4-expressing tumors, and CRB-913, an orally delivered highly peripherally restricted CB1 inverse agonist for the treatment of obesity. Corbus is headquartered in Norwood, Massachusetts.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- corbuspharma.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.